Ignyta (RXDX) Stock Declines After Pricing Secondary Offering

NEW YORK (TheStreet) -- Ignyta (RXDX) shares are down 6.24% to $17.27 in early afternoon trading on Thursday after the development stage biopharmaceutical company priced the secondary offering of 4,285,714 million shares at $17.50 per share.

The gross proceeds from the offering are expected to be approximately $75 million before deducting discounts and commissions. Underwriters will be granted 30 days to purchase up to an additional 642,857 shares.

The offering is expected to close June 16.

The company said that it plans to use proceeds from the offering to fund research and development programs.

RXDX Chart RXDX data by YCharts

If you liked this article you might like

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Dow, S&P 500 and Nasdaq Finish Lower After Trump Signs Tax Bill Into Law

Dow, S&P 500 and Nasdaq Finish Lower After Trump Signs Tax Bill Into Law

Stocks Trade Lower After Trump Signs Tax Bill Into Law

Stocks Trade Lower After Trump Signs Tax Bill Into Law

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Stocks Trade Lower but Remain On Track for Weekly Gains

Stocks Trade Lower but Remain On Track for Weekly Gains